Quantoom Biosciences

What we do: Quantoom Biosciences is a full-stack RNA partner specializing in mRNA- and saRNA-based vaccines and therapeutics. The company offers an innovative N-Force toolbox comprising three core elements: Ncode for sequence design and optimization, Ntensify® for scalable RNA production, and Ncapsulate® for RNA-LNP formulation. These technologies enable the transformation of any antigen into a (sa)mRNA-LNP drug product. Quantoom supports its partners with strategic R&D collaborations and extensive enabling solutions across synthetic biology, nucleic acids, bioproduction, vaccines, and therapeutics.

Where we are located: The company is headquartered at Rue de la Maîtrise 11, 1400 Nivelles, Walloon Region, Belgium.

Short history: Founded in 2021, Quantoom Biosciences has quickly established itself as a leader in RNA bioprocessing technology. In 2023, it launched the Ntensify solution, which integrates processes, equipment, reagent mixes, and disposables for fully scalable RNA production. The company has gained global adoption and recognition for performance and ease-of-use.

Organization & culture: Quantoom Biosciences employs approximately 128 people. While specific cultural details are not publicly detailed, the company emphasizes innovation, collaboration, and enabling partners through advanced RNA technologies.

Recent developments: In 2023, Quantoom launched the Ntensify platform, enhancing integrated RNA production capabilities. The company has also formed strategic partnerships, including a research license and supply agreement with Memorial Sloan Kettering Cancer Center to advance personalized cancer therapeutics.